4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
NewAmsterdam Pharma Company N.V. (NAMS) operates in the Biotechnology industry and is headquartered in Naarden, Netherlands with about 100 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, NAMS reported $22M in revenue and ($204M) in net income.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
Interactive charts & full statements → Open the NAMS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $22M | $46M | $14M | $103M | — |
| Operating Income (EBIT) | ($226M) | ($176M) | ($183M) | ($4M) | — |
| Net Income | ($204M) | ($242M) | ($177M) | ($23M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $3M | $0M | $0M | $19M | $3M |
| Operating Income (EBIT) | ($58M) | ($66M) | ($55M) | ($36M) | ($69M) |
| Net Income | ($48M) | ($75M) | ($72M) | ($17M) | ($40M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $769M | $865M | $347M | $478M | — |
| Total Liabilities | $86M | $107M | $59M | $48M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NAMS viewer.
About TickerBase · Data methodology & sources